Yardley, D. A., Brufsky, A., Coleman, R. E., Conte, P. F., Cortes, J., Glück, S., . . . Harbeck, N. (2016). Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials.
Chicago Style aipamenaYardley, Denise A., et al. "Erratum To: ‘Phase II/III Weekly Nab-paclitaxel Plus Gemcitabine or Carboplatin Versus Gemcitabine/carboplatin As First-line Treatment of Patients With Metastatic Triple-negative Breast Cancer (the TnAcity Study): Study Protocol for a Randomized Controlled Trial." Trials 2016.
MLA aipamenaYardley, Denise A., et al. "Erratum To: ‘Phase II/III Weekly Nab-paclitaxel Plus Gemcitabine or Carboplatin Versus Gemcitabine/carboplatin As First-line Treatment of Patients With Metastatic Triple-negative Breast Cancer (the TnAcity Study): Study Protocol for a Randomized Controlled Trial." Trials 2016.